Glenmark Pharmaceuticals Ltd. has appointed Dr. Kurt Stoeckli as president and chief scientific officer (CSO). Dr. Stoeckli joins Glenmark from Sanofi where he was group vice president, global biopharmaceuticals division & chief scientific officer for R&D France. He will report to Glenn Saldanha, chairman and MD and will be based out of Neuchâtel, Switzerland. He will also be president and general manager of Glenmark’s Switzerland-based business units. Dr. Stoeckli will lead the company’s global research portfolio consisting of NBE, NCE, generics and branded formulations. He will be responsible for sustaining and enhancing the environment of collaborative research and for driving successful commercialization of Glenmark’ research pipeline in partnership with other leaders.